Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 3 selected

Type

Guidance programme 4 selected

Guidance programme

Showing 1 to 10 of 933

TitleReference numberPublishedLast updated
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036
Epilepsies in children, young people and adultsNG217
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney diseaseTA1035
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal)TA1032
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumoursTA1034
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and overTA1031

Results per page

  1. 10
  2. 25
  3. 50
  4. All